



## ORIGINAL ARTICLE

# Serogroup C invasive meningococcal disease in the post-vaccine era and vaccine failures<sup>☆,☆☆</sup>

Neus Rius<sup>a</sup>, Mayli Lung<sup>b</sup>, Carolina Fernández-San José<sup>c</sup>, Tamara Iglesias<sup>d</sup>,  
Juliana Esperalba<sup>b</sup>, Fernando A. Moraga-Llop<sup>d,\*</sup>, Pere Soler-Palacín<sup>d</sup>

<sup>a</sup> Servicio de Pediatría, Hospital Universitari Sant Joan de Reus, Reus (Tarragona), Spain

<sup>b</sup> Servicio de Microbiología, Hospital Universitari Vall d'Hebron, Barcelona, Spain

<sup>c</sup> Servicio de Pediatría, CAP La Sagrera, Barcelona, Spain

<sup>d</sup> Unidad de Patología Infecciosa e Inmunodeficiencias de Pediatría, Hospital Infantil Universitari Vall d'Hebron, Barcelona, Spain

Received 3 October 2019; accepted 12 February 2020

Available online 15 November 2020

### KEYWORDS

Invasive meningococcal disease;  
Epidemiology;  
Polymerase chain reaction;  
Serogroup C meningococcus;  
Serogroup B meningococcus;  
Meningitis C conjugated vaccine;  
Vaccine failure

### Abstract

**Introduction:** The incidence of serogroup C invasive meningococcal disease (IMD) has decreased since the introduction of systematic vaccination in 2000. The aim of this study is to determine the number of serogroup C IMD cases diagnosed since then and the vaccine failures.

**Patients and methods:** A retrospective analysis was performed on patients diagnosed with IMD by culture or polymerase chain reaction (PCR) in a maternity and childhood hospital in Barcelona between 2001 and 2018. An analysis was made of the number of vaccine doses and the age received, as well as on the medical records and vaccine cards.

**Results:** There were 128 confirmed cases of IMD (7.1 cases/year; 70.3 in <5 years). The serogroup was studied in 125 (97.6%) cases, in which 103 (82.4%) were B, 10 (8%) were C, 1 (0.8%) was 29E, and 1 (0.8%) was Y, and only 10 (8%) were not able to be serogrouped. Of the 10 patients with serogroup C, 4 were not vaccinated, and in 3, the course was not complete as regards the number of doses. The other 3 received the complete course according to age and current calendar, and thus were considered vaccine failures. A total of 6 patients died (mortality rate: 4.7%), 5 due to serogroup B (mortality: 4.8%), and 1 due to serogroup C (mortality: 10%).

**Conclusions:** Serogroup C only represented 8% (10 cases) of IMD cases in the period studied, 3 cases due to this serogroup being vaccine failures.

© 2020 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<sup>☆</sup> Please cite this article as: Rius N, Lung M, Fernández-San José C, Iglesias T, Esperalba J, Moraga-Llop FA, et al. Enfermedad meningocócica invasiva por serogrupo C en la era posvacunal y fallos vacunales. An Pediatr (Barc). 2020;93:396–402.

<sup>☆☆</sup> Previous presentation: Data from this study were presented at the X National Congress of the Asociación Española de Vacunología, October 3–5, 2019, Oviedo, Spain.

\* Corresponding author.

E-mail address: [fmoraga@acmcb.es](mailto:fmoraga@acmcb.es) (F.A. Moraga-Llop).

**PALABRAS CLAVE**

Enfermedad meningocócica invasiva;  
Epidemiología;  
Reacción en cadena de la polimerasa;  
Meningococo serogrupo C;  
Meningococo serogrupo B;  
Vacuna conjugada antimeningocócica C;  
Fallo vacunal

**Enfermedad meningocócica invasiva por serogrupo C en la era posvacunal y fallos vacunales****Resumen**

**Introducción:** La incidencia de la enfermedad meningocócica invasiva (EMI) por serogrupo C ha disminuido desde la introducción de la vacunación sistemática en 2000. El objetivo de este estudio es determinar los casos de EMI diagnosticados desde entonces y los fallos vacunales en los casos por serogrupo C.

**Pacientes y métodos:** Análisis retrospectivo de pacientes diagnosticados de EMI confirmada por cultivo o reacción en cadena de la polimerasa, en un hospital materno infantil de tercer nivel de Barcelona, entre 2001 y 2018. Se analizó el número de dosis de vacuna recibidas y la edad, recogidos de la historia clínica y del carnet de vacunaciones.

**Resultados:** Se confirmaron 128 casos de EMI (7,1 casos/año; 70,3% en <5 años). Se estudió el serogrupo en 125 casos (97,6%): 103 fueron B (82,4%), 10 fueron C (8%), 1 fue 29E (0,8%) y 1 fue Y (0,8%); solo 10 (8%) no fueron serogrupables. De los 10 pacientes con serogrupo C, 4 no estaban vacunados y en 3 la pauta fue incompleta en cuanto a número de dosis; 3 de ellos recibieron la pauta completa según la edad y el calendario vacunal vigente, por lo que se consideran fallos vacunales. Fallecieron 6 pacientes (tasa letalidad: 4,7%): 5 por serogrupo B (letalidad: 4,8%) y 1 por serogrupo C (letalidad: 10%).

**Conclusiones:** El serogrupo C representó solo el 8% (10 pacientes) de los casos de EMI en el periodo de estudio siendo 3 de los casos por este serogrupo fallos vacunales.

© 2020 Asociación Española de Pediatría. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Introduction**

Invasive meningococcal disease (IMD) continues to be an important public health problem on account of its mortality, the high proportion of patients that develop sequelae, the significant impact on families and the social alarm that it generates.<sup>1,2</sup>

*Neisseria meningitidis* is a gram-negative diplococcus and strictly human pathogen that adheres to the surface of mucosal cells in the nasopharynx, resulting in an asymptomatic carrier status. Nasopharyngeal colonization is a necessary condition for IMD to develop. The carriage prevalence ranges from 4.5% in infants and 23.7% in individuals aged 19 years, thereby decreasing until reaching 7.8% in individuals aged 50 years.<sup>3,4</sup> Individuals that carry the pathogen in the nasopharynx can transmit the infection to young children, adolescents and elderly adults, which are the age groups in which the incidence of IMD is highest.

There are 12 serogroups of *N. meningitidis*, of which 6 (A, B, C, W, Y and X) cause more than 95% of cases of meningococcal disease.<sup>5,6</sup> Prevention through vaccination is available for 5 of these serogroups, and 5 types of vaccines are currently available: 2 conjugate monovalent vaccines for groups A and C (MenC conjugate vaccine); one conjugate quadrivalent vaccine (ACWY), and 2 non-conjugated vaccines against group B. Three pentavalent vaccines are currently undergoing trials,<sup>7-9</sup> one of which includes group X (ACWYX), of great interest for the African continent, and 2 others that include group B (ABCWY), more applicable to Europe.

In Spain, the incidence of meningococcal disease has decreased significantly in the past 20 years, in part thanks

to the introduction of routine vaccination with the MenC conjugate vaccine in 2000 followed by excellent vaccine coverages. Elective vaccination against serogroup B, which has been available since 2015, may also have contributed, as there is evidence of cross-protection against serogroup C.<sup>10</sup> Nevertheless, meningococcal disease continues to be serious and associated with a high mortality. Based on data from the national epidemiological surveillance system of Spain,<sup>11</sup> in the 2017-2018 period there were 346 confirmed cases, corresponding to an incidence of 0.74 confirmed cases per 100 000 inhabitants and a 76.2% increase relative to the 2013-2014 period (195 cases and incidence of 0.42); in the late 1990s, before the introduction of vaccination against meningococcal C disease, the incidence of IMD peaked at 4 cases per 100 000 inhabitants. However, considering the data by age group, the incidence in the latter period was much higher in children aged less than 1 year (8.65 cases per 100 000 inhabitants). Among the confirmed cases, 41% corresponded to serogroup B, 13.9% to serogroup W, 11.6% to serogroup C and 10.7% to serogroup Y. The rest of the cases corresponded to nontypeable strains (9.2%), serogroups less prevalent in Spain (1.1%), or a serogroup that had not been determined (12.1%).<sup>11</sup>

Despite the high vaccine coverage rate, cases of IMD caused by serogroup C have been notified in recent years.<sup>11-17</sup> We ought to highlight an increase in the number of cases caused by serogroup C in the last documented period, 2017-2018 (40 cases), compared to 2013-2014 (15 cases).<sup>11</sup> Nevertheless, from the time it was included in the routine vaccination schedule, vaccination against meningococcal C disease has had a significant impact in controlling the disease.<sup>11,12,18</sup>

The aim of our study was to analyse the cases of IMD that required admission to a tertiary care hospital from the time the MenC conjugate vaccine was included in the routine immunization schedule of the autonomous community of Catalonia in 2000, analyse the serogroup distribution of the cases, and determine the vaccination status of patients with meningococcal C disease.

## Patients and methods

We conducted a retrospective analysis of the health records of patients aged less than 16 years with a diagnosis of IMD confirmed by culture or gene amplification (polymerase chain reaction [PCR]), admitted to our hospital (a tertiary referral children's hospital with more than 3000 admissions per year and 41 intensive care beds) between January 2001 and December 2018. We collected data on the microbiological tests performed and epidemiological and clinical variables.

## Microbiological testing

We retrieved the results of culture or PCR in blood or cerebrospinal fluid (CSF) samples. Blood samples were cultured in Bact/Alert® bottles (bioMérieux; Marcy-l'Étoile, France) and CSF samples, following centrifugation, were cultured in conventional solid media and enriched liquid media. All samples were incubated for 5 to 6 days. Culture isolates were identified by biochemical tests or protein fingerprinting (Vitek®2 NH Card or the Vitek MS MALDI-TOF mass spectrometry identification system, respectively, bioMérieux; Marcy-l'Étoile, France). In the interpretation of antimicrobial susceptibility tests, we applied the cut-off points recommended in the guidelines of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standard Institute. In the molecular analysis of CSF, sample volumes of at least 100 µL were used to perform multiplex real-time PCR for detection of *N. meningitidis* (ctrA region, capsular transport gene), *Haemophilus influenzae* type b (*bexA*, capsulation gene) and *Streptococcus pneumoniae* (*ply*, pneumolysin gene) using TaqMan® fluorescent probes in a SmartCycler® thermal cycler (Cepheid, Sunnyvale, USA).<sup>19</sup> Serotyping of *N. meningitidis* was done by slide agglutination tests with specific antisera to groups B and C (Difco™ *Neisseria meningitidis* Antiserum Group B/Group C; Becton Dickinson, Sparks, MD, USA) or by real-time PCR for detection of groups B, C, W and Y.<sup>20,21</sup> We submitted strains that could not be typed in our laboratory to the Neisseria Reference Laboratory of the National Microbiology Centre of the Instituto de Salud Carlos III in Majadahonda (Madrid, Spain), where strain 29E was identified, among others.

## Epidemiological variables

We collected demographic data and information about the MenC conjugate vaccine in patients with disease caused by group C. We retrieved the number of doses of vaccine received and the age at the time of vaccination from the personal vaccination card and the health records of the

patients. We established the following vaccination status categories:

- Unvaccinated: patient that had not received a single dose of MenC vaccine at the time of diagnosis.
- Incomplete vaccination: patient that had received fewer doses than established for their age in the current routine immunization schedule at the time of diagnosis.
- Vaccine failure: patient with complete vaccination for age based on the routine immunization schedule at the time of diagnosis that had symptoms of the disease at least 14 days after the last dose of vaccine.

## Clinical variables

We retrieved data on the presentation of IMD and the results of the functional complement assays performed in the patients for screening of immunodeficiencies (classic haemolytic complement [CH50] and alternative haemolytic complement [AP50]).


## Results

Between January 2001 and December 2018, our hospital admitted 128 patients with a clinical diagnosis of IMD (7.1 patients/year) subsequently confirmed by culture, PCR or both in blood or CSF samples. The case distribution was homogeneous during the first years under study (6-10 cases per year), followed by a slight increase in 2009 and 2010 (17 and 13 cases, respectively) and a decreasing trend in the years that followed, with the lowest incidence recorded in 2013 (Fig. 1).

There was a predominance of male patients (79 boys and 49 girls), and the age range of the sample was 1 month to 16 years (median, 2 years; interquartile range, 9 months-5 years). Of the 128 patients, 90 were aged less than 5 years (70.3%) and one fourth were aged less than 1 year (34; 26.6%). When it came to the clinical diagnosis, 68 patients (53.1%) presented with sepsis, 39 (30.5%) with meningitis and 21 (16.4%) with sepsis associated with meningitis. Six patients died (mortality, 4.7%), 5 with infection by group B and 1 with infection by group C, corresponding to a mortality of 4.8% and 10%, respectively; the deceased patient with meningococcal C disease was an unvaccinated male adolescent. Table 1 highlights the main differences in the demographic and clinical characteristics of patients with meningococcal C disease compared to those with disease by other serogroups.

The results of culture were positive in 92 patients and negative in 36 (28.1%). Molecular testing by PCR analysis of blood or CSF samples was performed in 95 patients and yielded positive results in 86 (90.5%). Of the patients that had positive results of PCR tests, 41.9% had negative culture results. Of all isolated strains, 120 were subjected to antibiotic susceptibility testing: 105 were susceptible to penicillin (87.5%), 12 exhibited intermediate penicillin resistance and 3 were resistant to penicillin but susceptible to third generation cephalosporins.

Serotyping was performed in 125 of the 128 cases (97.6%). There was a high proportion of group B strains, detected in 103 cases (82.4%); 10 were group C cases (8%), mostly clus-



**Figure 1** Distribution of cases of invasive meningococcal disease by serogroup and year.

**Table 1** Comparison of the group of patients with invasive meningococcal disease by serogroups other than C and patients with invasive meningococcal disease by serogroup C.

	Serogroup other than C (n = 118)	Serogroup C (n = 10)
<b>Age</b>	1 month-16 years (median, 1 year; IQR, 7 months-5 years)	1-15 years (median, 5.5 years; IQR, 1 year-9 years)
<5 years	87 (73.7%)	3 (30%)
<1 year	34 (28.8%)	0
<b>[0,1-3]Sex, n (%)</b>		
Male	74 (62.7)	5 (50)
Female	44 (37.3)	5 (50)
<b>[0,1-3]Clinical presentation, n (%)</b>		
Sepsis	61 (51.7)	7 (70)
Meningitis	38 (32.2)	1 (10)
Sepsis con meningitis	19 (16.1)	2 (20)
<b>[0,1-3]Mortality (%)</b>	4.2	10

IQR, interquartile range.

tered in the early period under study, and 2 corresponded to serogroups Y and 29E. Only 10 cases (8%) were nontypeable, whereas the serogroup could not be established in the remaining 3 (Fig. 1).

Functional complement assays were performed in 86 patients and detected deficiencies in 3 (3.5%): 2 patients with serogroups with a low prevalence in Spain (serogroups Y and 29E) and 1 patient with infection by an unknown serogroup. All 3 patients had C5 deficiency, and had addi-

tional risk factors for immunodeficiency (consanguinity, positive family history...).

Table 2 summarises the vaccination history of the 10 patients with invasive meningococcal C disease. Four of the patients were unvaccinated, 3 patients aged 2, 5 and 10 years had an incomplete vaccination status (the first 2 had only received 2 doses before age 1 year, and the patient aged 10 years did not receive the catch-up dose recommended in the updated routine vaccination schedule). The 3 remaining patients, aged 1, 9 and 7 years, were fully vaccinated based on their age and the current routine immunization schedule, having received 3 doses (1 patient, 3 doses in the first year of life, and the other 2 patients in a 2 + 1 schedule).

## Discussion

Invasive meningococcal disease is a global health problem that is endemic in most countries and can also occur in the context of outbreaks. It most frequently manifests in the form of meningitis (in 50% to 70% of cases),<sup>22</sup> although in our case series the most frequent presentation was sepsis, in 53.1% of the total, while meningitis was observed in 30.5% and both sepsis and meningitis in 16.4%. The mortality in cases of meningococcal C disease was double that of cases of meningococcal B disease (10% vs 4.8%). As described in the previous literature, the patients at highest risk were the youngest children: 70% of cases occurred in children under 5 years and 38% of children in this group were aged less than 1 year; patients with group C disease were older, and only 30% were aged less than 5 years. In light of this, the Advisory Committee on Vaccines of the Asociación Española de Pediatría (Spanish Association of Paediatrics) (CAV-AEP) recommends routine vaccination against serogroup B, which is the most prevalent (67.6%), with an incidence of 5.85 confirmed cases per 100 000 in infants aged less than 12 months.<sup>11</sup>

The development of molecular techniques constituted a breakthrough in the microbiological diagnosis of IMD, as these methods are more sensitive, specific and quick and

**Table 2** Vaccination history of patients with invasive meningococcal disease caused by serogroup C.

Case	Year of diagnosis	Age at time of diagnosis	Doses of vaccine	Vaccination status
1	2001	6 years	0	Unvaccinated
2	2001	15 months	0	Unvaccinated
3	2001	6 years	0	Unvaccinated
4	2003	15 years	0	Unvaccinated
5	2007	2 years	2 in 1 <sup>st</sup> year	Incomplete vaccination
6	2008	5 years	2 in 1 <sup>st</sup> year	Incomplete vaccination
7	2012	10 years	3 in 1 <sup>st</sup> year	Incomplete vaccination
8	2004	13 months	3 in 1 <sup>st</sup> year	Vaccine failure
9	2017	9 years	3 (2 + 1 schedule) <sup>a</sup>	Vaccine failure
10	2018	7 years	3 (2 + 1 schedule) <sup>a</sup>	Vaccine failure

<sup>a</sup> Two doses in 1<sup>st</sup> year of life and 1 dose at age 15 months.

their results are not influenced by the administration of antibiotics before the sample is obtained.<sup>23–25</sup> The use of these techniques made it possible to confirm the diagnosis in 28.1% of the patients, who had negative culture results probably due to initiation of antibiotherapy before testing. Nevertheless, culture remains the gold standard of diagnosis, in addition to allowing performance of antimicrobial susceptibility testing and serotyping of isolated strains, which is very important for the purpose of epidemiological surveillance.

Since the MenC conjugate vaccine was included in the routine immunization schedule, there have been 3 vaccination schedules. Initially, in 1999, the Interterritorial Council of the National Health System (known as the CISNS) approved the recommendation of including the MenC conjugate vaccine in the official immunization schedule,<sup>13</sup> which was introduced in the schedules of every autonomous community of Spain in 2000 with 3 doses at ages 2, 4 and 6 meses (and in the 2001 immunization schedules published by the CISNS and the CAV-AEP). In January 2006, the vaccination schedule changed to primary vaccination with 2 doses given in the first year of life and a booster dose in the second year of life (as featured in the 2005 schedule of the CAV-AEV and the 2007 schedule of the CISNS), as evidence showed that vaccine effectiveness dwindled with time and that the antibody titre decreased more rapidly with vaccination in the first year of life<sup>14</sup> (only 30% of children that received primary vaccination continued to be protected at age 5 years). The percentage of immunised children increases with the age at vaccination to up to 70% at 10 years post-vaccination in individuals given 1 dose of vaccine at age 16 years.<sup>15</sup> For this reason, a third schedule was introduced in 2014 in which one of the primary vaccination doses is eliminated, and a second booster dose added in adolescence (as established in the immunization schedules published by the CISNS in 2013 and the CAV-AEV in 2014).<sup>13,15</sup>

These 3 schedules are an example of a dynamic vaccination strategy based on the epidemiology of the disease and the monitoring of vaccine effectiveness over time. This dynamic approach to vaccination continues, and this year a

new change is being introduced: in this instance, the third dose of monovalent MenC vaccine is being replaced by a dose of quadrivalent MenACWY vaccine (2019 schedule of the CISNS) due to the observed epidemiological changes in the prevalence of meningococcal serogroups.

Following the introduction of the MenC conjugate vaccine in the routine immunization schedule, the incidence of meningococcal C disease decreased considerably,<sup>11,12,18</sup> although there have been cases of vaccine failure—primary vaccine failure when the patient does not produce a sufficient concentration of antibodies after vaccination, and secondary vaccine failure when the patient can initially mount an adequate antibody response but the response wanes over time, which is the predominant type of failure in IMD.<sup>14</sup> When it comes to the persistence of antibodies, several studies have generally evinced decreasing titres as time passes after vaccination, especially if primary vaccination took place in the first two years of life.<sup>14</sup> The protective immune response following the primary series in the first year of life wanes quickly, so a booster dose is needed in the second year of life. Primary vaccination in the second year of life also confers protection that wanes within a few years and is insufficient in the long term, while vaccination from age 5 years achieves antibody titres closer to those achieved by naturally acquired active immunity, which also increase with the age at the time of vaccination.<sup>25–29</sup>

Studies conducted in Spain have demonstrated that vaccine effectiveness decreases after 1 year postvaccination, especially in individuals vaccinated in the first year of life, and that age at the time of primary vaccination and the time elapsed from the last dose are 2 of the most important factors at play in vaccine failure.<sup>14,30</sup>

Of the 10 patients with IMD caused by serogroup C in our study, 4 had not received any doses of vaccine and 3 had incomplete vaccination for their ages based on the current immunization schedule. The 3 remaining patients were cases of vaccine failure, as their vaccinations were up to date based on their age and the official immunization schedule. In 2 of these children, aged 9 and 7 years (cases 9 and 10), more than 5 years had elapsed since the last dose had been



administered, which was probably the reason for the low levels of circulating antibodies (secondary vaccine failure). The third child (case 8), aged 13 months, had received the 3 doses of the primary vaccination series established by the official immunization schedule at the time, so this case could be attributed to primary vaccine failure.

Ongoing epidemiologic surveillance, even in diseases with a decreasing incidence, as is the case of IMD caused by serogroup C, is very important for the purpose of assessing vaccine effectiveness as years go by and to implement new interventions or adapt vaccination strategies, as was done in 2000. The introduction of a booster dose in the second year of life, first, and subsequently of a second booster dose in adolescence was motivated by studies demonstrating the waning of immunity with increasing time elapsed after primary vaccination.

## Conflicts of interest

FAML has received fees from GSK and Pfizer as a consultant and to be a speaker in scientific conferences. The rest of the authors have no conflicts of interest to declare in relation to this study.

## References

- Vázquez JA. Situación actual de la epidemiología de la enfermedad meningocócica. *Enferm Infecc Microbiol Clin.* 2006;24 Supl 1:14–8.
- Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. *Pediatr Infect Dis J.* 2004;23 12 Suppl:S274–9.
- Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010;10:853–61.
- Domínguez A, Cardeñoso N, Izquierdo C, Sánchez F, Margall N, Vázquez JA, et al. Prevalence of *Neisseria meningitidis* carriers in the school population of Catalonia, Spain. *Epidemiol Infect.* 2001;127:425–33.
- Baker CJ. Prevention of meningococcal infection in the United States: current recommendations and future considerations. *J Adolesc Health.* 2016;59:S29–37.
- Soult Rubio JA, Muñoz Sáez M. Enfermedad meningocócica invasora. *An Pediatr (Barc).* 2005;62:297–303.
- Chen WH, Neuzil KM, Boyce CR, Pasetti MF, Reymann MK, Martellet L, et al. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. *Lancet Infect Dis.* 2018;18:1088–96.
- Welsch J, Senders S, Essink B, Klein T, Smolenov I, Pedotti P, et al. Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents – results from a randomized, controlled, observer-blind phase II study. *Vaccine.* 2018;36:5309–17.
- ClinicalTrials.gov. A trial to describe the immunogenicity and safety of 2 doses of bivalent rLP2086 (Trumenba) and a pentavalent meningococcal vaccine in healthy subjects >=10 to <26 years of age [Accessed 24 February 2019]. Available from: <https://clinicaltrials.gov/ct2/show/NCT03135834?cond=meningococcal+vaccines&rank=1>.
- Ladhani SN, Giuliani MM, Biotchi A, Pizza M, Beebejaun K, Lucidarme J, et al. Effectiveness of meningococcal B vaccine against endemic hypervirulent *Neisseria meningitidis* W strain, England. *Emerg Infect Dis.* 2016;22:309–11.
- Red Nacional de Vigilancia Epidemiológica. Enfermedad meningocócica. Vigilancia de la temporada 2017-2018 [Accessed 16 February 2019]. Available from: <http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnico/fd-vigilancias-alertas/fd-enfermedades/fd-enfermedades-prevenibles-vacunacion/pdf.2019/RENAVE.EMI-2017-18.pdf>.
- Morales D, García-Cenoz M, Moreno L, Bernaola E, Barricarte A, Castilla J. Vacuna conjugada frente al meningococo C: impacto del programa de vacunación y efectividad a largo plazo en Navarra, 2000-2014. *Enferm Infecc Microbiol Clin.* 2016;34:639–44.
- Grupo de Trabajo MenCC 2012, de la Ponencia de Programas y Registro de Vacunaciones. Revisión de la pauta de vacunación frente a enfermedad meningocócica por serogrupo C. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2013.
- Garrido-Esteba M, Nuñez OG, León-Gómez I, Cano R, Herruzo R. Meningococcal C conjugate age-dependant long-term loss of effectiveness. *Vaccine.* 2015;33:2221–7.
- Díez Domingo J. Nueva pauta de vacunación frente al meningococo C. In: Campins Martí M, Moraga Llop FA, editors. *Vacunas 2014*. Barcelona: Gráficas Campás; 2014. p. 85–93.
- Cano Portero R, Garrido Esteba M. Enfermedad meningocócica en España. Análisis de la temporada 2009-2010. *Bol Epidemiol Sem.* 2011;19:233–46.
- Salas Butrón M., Martínez Pino I., Rodríguez Recio M.J., Ruiz Sopena C., Fernández Arribas M.S., Tamames Gómez S., et al. Vaccine failures after meningococcal C conjugate vaccine. Seasons 2000/2001 to 2017/2018, Castilla y León (Spain). Presentado en: European Society for Paediatric Infectious Diseases (ESPID), May 6-11, 2019, Ljubljana, Slovenia (Accessed 16 July 2019). Available from: <https://ativsoftware.com/appinfo.php?page=Inhtml&project=ESPID19&server=eventpilot.us&id=abstract.66144>.
- Garrido-Esteba M, León-Gómez I, Herruzo R, Cano R. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification. *Vaccine.* 2014;32:2604–9.
- Corless CE, Guiver M, Borrow R, Edwards-Junes V, Fox AJ, Kaczmarek EB. Simultaneous detection of *Neisseria meningitidis*, *Haemophilus influenzae*, and *Streptococcus pneumoniae* in suspected cases of meningitis and septicemia using real-time PCR. *J Clin Microbiol.* 2001;39:153–8.
- Mölling P, Jacobsson S, Bäckman A, Olcén P. Direct and rapid identification and genotyping of meningococci and porA amplification by LightCycler PCR. *J Clin Microbiol.* 2002;40:4531–5.
- Rojas E, Hoyos J, Oldfield NJ, Lee P, Flint M, Jones CH, et al. Optimization of molecular approaches to genogroup *Neisseria meningitidis* carriage isolates and implications for monitoring the impact of new serogroup B vaccines. *PLoS One.* 2015;10:e0132140.
- Ruiz Contreras J, Casado Flores J. Formas clínicas de la enfermedad meningocócica. In: Moraga-Llop FA, editor. *La enfermedad meningocócica. Pasado, presente y futuro*. Sant Hilari Sacalm (Girona): Gráficas Montseny; 2013. p. 121–30.
- Drew RJ, Ó Maoldomhnaigh C, Gavin PJ, O'Sullivan N, Butler KM, et al. The impact of meningococcal polymerase chain reaction testing on laboratory confirmation of invasive meningococcal disease. *Pediatr Infect Dis J.* 2012;31:316–8.
- Codina Grau MG, Tórtola Fernández MT. Utilidad diagnóstica de la detección de ácidos nucleicos mediante reacción en cadena de la polimerasa realizada en tiempo real. *Enferm Infecc Microbiol Clin.* 2006;9:539–40.

25. Fernández-San José C, Moraga-Llop FA, Codina G, Soler-Palacín P, Espiau M, Figueras C. La reacción en cadena de la polimerasa en el diagnóstico de la enfermedad meningocócica invasiva. *An Pediatr (Barc)*. 2015;82:139–43.
26. Díez-Domingo J, Planelles-Cantarino MV, Baldo-Torrenti JM, Ubeda-Sansano I, Jubert-Rosich A, Puig-Barbera J, et al. Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life. *Pediatr Infect Dis J*. 2010;29:768–70.
27. Perrett KP, Winter AP, Kibwana E, Jin C, John TM, Yu LM, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. *Clin Infect Dis*. 2010;50:1601–10.
28. Ishola DA, Borrow R, Findlow H, Findlow J, Trotter C, Ramsay ME. Prevalence of serum bactericidal antibody to serogroup C *Neisseria meningitidis* in England a decade after vaccine introduction. *Clin Vaccine Immunol*. 2012;19:1126–30.
29. de Voer RM, Mollema L, Schepp RM, de Greeff SC, van Gageldonk PGM, de Melker HE, et al. Immunity against *Neisseria meningitidis* serogroup C in the Dutch population before and after introduction of the meningococcal C conjugate vaccine. *PLoS One*. 2010;5:e12144.
30. Larrauri A, Cano R, García M, de Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. *Vaccine*. 2005;23:4097–100.